<SEC-DOCUMENT>0001493152-25-018869.txt : 20251022
<SEC-HEADER>0001493152-25-018869.hdr.sgml : 20251022
<ACCEPTANCE-DATETIME>20251022080015
ACCESSION NUMBER:		0001493152-25-018869
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251022
FILED AS OF DATE:		20251022
DATE AS OF CHANGE:		20251022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CytoMed Therapeutics Ltd
		CENTRAL INDEX KEY:			0001873093
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41677
		FILM NUMBER:		251408623

	BUSINESS ADDRESS:	
		STREET 1:		#08-22 ONE COMMONWEALTH
		CITY:			1 COMMONWEALTH LANE
		STATE:			U0
		ZIP:			149544
		BUSINESS PHONE:		603824911

	MAIL ADDRESS:	
		STREET 1:		#08-22 ONE COMMONWEALTH
		CITY:			1 COMMONWEALTH LANE
		STATE:			U0
		ZIP:			149544

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CytoMed Therapeutics Pte. Ltd.
		DATE OF NAME CHANGE:	20210716
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of October 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number: 001-41677</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>CytoMed
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1
Commonwealth Lane</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>#08-22</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Singapore
149544</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Office)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS FORM 6-K REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 22, 2025, CytoMed Therapeutics Limited (the &ldquo;Company&rdquo;) issued a press release announcing that its Executive Chairman
and substantial shareholder, Mr Choo Chee Kong has increased his shareholding in the Company through recent open-market purchases of
105,824 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.65in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.1in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press Release dated October 22, 2025, titled: &ldquo;CytoMed Therapeutics&rsquo; Chairman Increases Effective Holdings to 21.95%&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
    Therapeutics Limited</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    CHOO Chee Kong</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHOO
    Chee Kong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    October 22, 2025</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chairman</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT="" style="width:120px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
Therapeutics&rsquo; Chairman Increases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective
Holdings to 21.95%</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Singapore,
Singapore &ndash; (October 22, 2025) &ndash;</B> <U>CytoMed Therapeutics Limited</U> (NASDAQ: GDTC) (&ldquo;CytoMed&rdquo; or &ldquo;Company&rdquo;),
a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today
announced that its Executive Chairman and substantial shareholder, Mr Peter Choo has increased his shareholding in the Company through
recent open-market purchases of 105,824 shares. This is on top of 187,500 shares which he holds personally, bringing his personal stake
in CytoMed to 2.50% as of today. In addition, our Chairman is also a 55% shareholder of Glorious Finance Limited, and the sole shareholder
of EP Capital Inc, representing 2,282,422 shares, or 19.45% of the Company. In aggregate, he owns 2,388,246 shares representing 21.95%
of the Company&rsquo;s total outstanding shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
his purchases, Chairman Peter remarked &ldquo;I see value and potential in our novel proprietary technologies to treat cancers in an
affordable and &ldquo;off-the-shelf&rdquo; manner amidst rising investors&rsquo; interest in biotherapeutics in Asia, especially China.
In addition, Southeast Asia&rsquo;s </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanding healthcare
and medical travel ecosystem, coupled with the rising cost of healthcare in the West, present unique opportunities to those who can innovate
and provide cost-competitive patient access. <FONT STYLE="background-color: white">T</FONT>he region&rsquo;s accelerating biotech momentum,
M&amp;A opportunities and supportive regulatory environment further reinforces my purchase decision.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will provide updates on further purchases by our Chairman and will announce when available. Shareholders and investors are advised
to exercise caution when dealing in the Company&rsquo;s securities until further announcements are made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
CytoMed Therapeutics Limited (CytoMed)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore&rsquo;s leading research and development
agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies,
namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for
the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T
therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating
the CAR-T principle into the treatment of solid tumours. For more information, please visit <U>www.cytomed.sg</U> and follow us on Twitter
(&ldquo;X&rdquo;) <U>@CytomedSG</U>, on <U>LinkedIn</U>, and <U>Facebook</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions
and other statements that are other than statements of historical facts. When the Company uses words such as &ldquo;may, &ldquo;will,
&ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo;
&ldquo;estimate&rdquo; or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results
to differ materially from the Company&rsquo;s expectations discussed in the forward-looking statements. These statements are subject
to uncertainties and risks including, but not limited to, the following: the Company&rsquo;s plans to develop and commercialize its product
candidates; the initiation, timing, progress and results of the Company&rsquo;s current and future pre-clinical studies and clinical
trials and the Company&rsquo;s R&amp;D programs; the Company&rsquo;s estimates regarding expenses, future revenue, capital requirements
and needs for additional financing; the Company&rsquo;s ability to successfully acquire or obtain licenses for additional product candidates
on reasonable terms; the Company&rsquo;s ability to establish and maintain collaborations and/or obtain additional funding and assumptions
underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional
factors are discussed in the Company&rsquo;s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes
no obligation to publicly revise these forward&ndash;looking statements to reflect events or circumstances that arise after the date
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enquiry@cytomed.sg</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention
: Evelyn Tan, Chief Corporate Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) )T# 2(  A$! Q$!_\0
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MFK8UBWLOETK2[: #_EK.OFRGWR>!7J/ZGA?=MSR_#^OO/$K8RI+6<N5=EO\
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M6,26YME*Q/ Y1E4]1GN*0^'K#['!;()8A YDCDCD(<,>ISW)HT*5*NG=RO\
MTO\ @F%J=S>WS/&+D1B'5EA3$8.!@8SZX-2R:A<VM]?P6_E+<3WL4"RE.!E
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5* "BBB@ I" 1@C-+10 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
